Acadia Healthcare Company stock has surged 127.4% year to date, yet its broader valuation checks still suggest the shares may be trading below what the fundamentals support.

• The year to date return of 127.4% highlights how quickly sentiment has shifted on Acadia Healthcare Company, which raises the bar for what the current price implies about future performance.
• For long term value, the key potential support is how consistently Acadia Healthcare Company can convert revenue into cash. A major risk is that any pressure on margins or higher funding needs could reduce that cash generation.
• Acadia Healthcare Company screens as undervalued on most metrics, with 5 out of 6 valuation checks pointing to a cheaper profile than the current share price might suggest.

The issue now is whether the current share price already reflects this rebound in expectations, or if Acadia Healthcare Company still offers a margin of safety.

Is Acadia Healthcare Company a Bargain on Sales?

P/S is a useful cross check for Acadia Healthcare Company because the business model is built on relatively steady service revenue rather than one off product sales. On this metric, the stock trades at about 0.9x trailing sales, which is below the Healthcare industry average of around 1.5x and also below the peer group average of about 1.5x.

The fair P/S ratio implied by the model for Acadia Healthcare Company is 1.3x. That sits between the current level and the wider industry, which indicates the shares are priced at a discount to what the company’s own revenue profile, scale and risk characteristics would typically support. Provided the company maintains its revenue base and avoids sharp pressure on margins, the gap between 0.9x and the 1.3x fair ratio may be viewed as potential support for investors who focus on sales-based valuation anchors.

On the P/S multiple, Acadia Healthcare Company stock appears inexpensive relative to both its tailored fair ratio and broader Healthcare peers.

The Acadia Healthcare Company Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Acadia Healthcare Company are designed to link this valuation puzzle to clear, testable assumptions about future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today's price, and they sit on the company’s Community page. Rather than relying on a single multiple or model line, each Narrative sets out the assumptions behind its view of fair value so you can compare those inputs to the company’s actual results over time.

The community is sharply split on Acadia Healthcare Company, with one camp focused on turnaround potential and the other on execution and regulatory risk.

Bull case: 17% undervalued

"Rapid facility openings and advanced technology adoption could drive faster revenue and margin growth than expected, outperforming consensus forecasts..."

Bear case: 172% overvalued

"The biggest risk for Acadia is not demand, it’s execution..."

Do you think there's more to the story for Acadia Healthcare Company? Head over to our Community to see what others are saying!

The Bottom Line

Acadia Healthcare Company screens as undervalued on the market multiples used here, which suggests investors are still pricing in a fair amount of execution and regulatory risk. The core question is whether the company can sustain its revenue base and protect margins well enough for that discount to close over time. For now, the gap between current trading multiples and the implied fair ratios looks like the main opportunity, while the risk is that ongoing operating or funding pressures prove the current markdown justified.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.